LT3098239T - Į egfr nukreipiamas dvigrandis rnr vektorius, skirtas sisteminiam vėžio gydymui - Google Patents

Į egfr nukreipiamas dvigrandis rnr vektorius, skirtas sisteminiam vėžio gydymui

Info

Publication number
LT3098239T
LT3098239T LTEP16177258.7T LT16177258T LT3098239T LT 3098239 T LT3098239 T LT 3098239T LT 16177258 T LT16177258 T LT 16177258T LT 3098239 T LT3098239 T LT 3098239T
Authority
LT
Lithuania
Prior art keywords
homing
egfr
double
stranded rna
cancer treatment
Prior art date
Application number
LTEP16177258.7T
Other languages
English (en)
Inventor
Alexander Levitzki
Alexei Shir
Original Assignee
Targimmune Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targimmune Therapeutics Ag filed Critical Targimmune Therapeutics Ag
Publication of LT3098239T publication Critical patent/LT3098239T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Information Transfer Between Computers (AREA)
LTEP16177258.7T 2008-12-22 2009-12-22 Į egfr nukreipiamas dvigrandis rnr vektorius, skirtas sisteminiam vėžio gydymui LT3098239T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13969808P 2008-12-22 2008-12-22

Publications (1)

Publication Number Publication Date
LT3098239T true LT3098239T (lt) 2020-02-10

Family

ID=42104511

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16177258.7T LT3098239T (lt) 2008-12-22 2009-12-22 Į egfr nukreipiamas dvigrandis rnr vektorius, skirtas sisteminiam vėžio gydymui

Country Status (19)

Country Link
US (2) US9006406B2 (lt)
EP (3) EP3098239B1 (lt)
JP (1) JP2012513210A (lt)
CN (1) CN102325794A (lt)
AU (1) AU2009332522A1 (lt)
BR (1) BRPI0922985A2 (lt)
CA (1) CA2748125A1 (lt)
CY (1) CY1123371T1 (lt)
DK (2) DK3098239T3 (lt)
ES (2) ES2602753T3 (lt)
HR (1) HRP20192317T1 (lt)
HU (1) HUE047759T2 (lt)
IL (1) IL213739A0 (lt)
LT (1) LT3098239T (lt)
MX (1) MX2011006720A (lt)
PL (1) PL3098239T3 (lt)
PT (1) PT3098239T (lt)
SI (1) SI3098239T1 (lt)
WO (1) WO2010073247A2 (lt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6349304B2 (ja) 2012-05-03 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー 上気道感染症の処置のためのポリイノシン−ポリシチジル酸(ポリ(i:c))製剤
JP6103832B2 (ja) 2012-06-25 2017-03-29 Hoya株式会社 Egfr結合性ペプチド
US9431064B2 (en) * 2012-11-02 2016-08-30 Taiwan Semiconductor Manufacturing Company, Ltd. Memory circuit and cache circuit configuration
US10796320B2 (en) * 2013-12-23 2020-10-06 Mastercard International Incorporated Systems and methods for passively determining a ratio of purchasers and prospective purchasers in a merchant location
WO2015173824A1 (en) * 2014-05-14 2015-11-19 Alex Levitzki Management And Holdings Ltd Improved polyethyleneimine polyethyleneglycol vectors
EP3274840A4 (en) * 2015-03-27 2018-12-26 Intel Corporation Dynamic cache allocation
CN112294757B (zh) * 2015-11-17 2024-02-13 亮点医疗有限责任公司 包含含有双链聚核糖核苷酸与聚亚烷基亚胺的复合物的粒子的医药组合物
GB201601868D0 (en) * 2016-02-02 2016-03-16 Lytix Biopharma As Methods
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药(苏州)股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
WO2018042411A1 (en) * 2016-09-04 2018-03-08 Alex Levitzki Management And Holdings, Ltd. Chimeric proteins for targeting dsrna
CN115998757A (zh) * 2017-05-17 2023-04-25 亮点医疗有限责任公司 包含具有双链多核糖核苷酸和聚乙烯亚胺的复合物的粒子的新型药物组合物
IL273195B2 (en) * 2017-09-27 2024-04-01 Targimmune Therapeutics Ag Castration-resistant prostate cancer
WO2020201568A1 (en) * 2019-04-03 2020-10-08 Targimmune Therapeutics Ag Immunotherapy for the treatment of cancer
WO2020263770A1 (en) * 2019-06-24 2020-12-30 North Carolina State University Nucleic acid compositions including a polyalkyleneimine-alkoxylene polymer and methods of making and using the same
WO2020263776A1 (en) * 2019-06-24 2020-12-30 North Carolina State University Nucleic acid compositions including a polyalkyleneimine-alkoxylene polymer and methods of making and using the same
US10915418B1 (en) * 2019-08-29 2021-02-09 Snowflake Inc. Automated query retry in a database environment
WO2024100044A1 (en) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927792B2 (en) 2002-11-18 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Targeted double stranded RNA mediated cell killing
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7937291B2 (en) * 2009-04-22 2011-05-03 Visa U.S.A. Inc. Providing an announcement about transactions of a target merchant to a consumer

Also Published As

Publication number Publication date
EP2379597A2 (en) 2011-10-26
AU2009332522A1 (en) 2011-08-11
DK3098239T3 (da) 2020-01-20
PL3098239T3 (pl) 2020-04-30
JP2012513210A (ja) 2012-06-14
EP2379597B1 (en) 2016-08-10
SI3098239T1 (sl) 2020-03-31
ES2602753T3 (es) 2017-02-22
WO2010073247A2 (en) 2010-07-01
PT3098239T (pt) 2020-01-15
HRP20192317T1 (hr) 2020-03-20
CA2748125A1 (en) 2010-07-01
BRPI0922985A2 (pt) 2016-10-04
US20120330998A1 (en) 2012-12-27
IL213739A0 (en) 2011-07-31
MX2011006720A (es) 2011-10-06
WO2010073247A3 (en) 2010-08-19
CN102325794A (zh) 2012-01-18
DK2379597T3 (en) 2016-12-05
EP2379597B8 (en) 2016-11-30
EP3098239B1 (en) 2019-10-23
EP3098239A1 (en) 2016-11-30
EP3705493A1 (en) 2020-09-09
US9006406B2 (en) 2015-04-14
HUE047759T2 (hu) 2020-05-28
ES2764396T3 (es) 2020-06-03
US20120021006A1 (en) 2012-01-26
CY1123371T1 (el) 2021-10-29

Similar Documents

Publication Publication Date Title
SI3098239T1 (sl) Egfr-homing vektor dvoverižne rna za sistemsko zdravljenje raka
GB2470672B (en) Methods of RNA amplification in the presence of DNA
EP2125032A4 (en) TREATMENT OF CANCER USING VIRAL NUCLEIC ACID
EP2310006A4 (en) TREATMENT OF CANCER
HK1165325A1 (en) Immunostimulatory oligonucleotides
GB0821457D0 (en) Oligonucleotides
GB0800702D0 (en) Genes
IL208374A0 (en) Double-stranded lipid-modified rna having high rna interference effect
IL238394A0 (en) Cancer treatment method
EP2253323A4 (en) ANTIALLERGENIC ACTIVE SUBSTANCE
EP2300017A4 (en) ARNMI AS THERAPEUTIC TARGETS IN CANCER
GB0804496D0 (en) Treating cancer
EP2144888A4 (en) METHODS OF TREATING CANCER
HK1141831A1 (en) Vector for gene therapy
EP2321641A4 (en) GENE METHYLATION IN THE DIAGNOSIS OF CANCER
GB0707556D0 (en) Treatment for cancer
GB0809046D0 (en) Cancer treatment
IL213735A0 (en) Egfr-homing double-stranded rna vector for systemic cancer treatment
GB0903562D0 (en) RNA molecules
GB0702681D0 (en) DNA-based biosensors
AU2008903338A0 (en) Ore Treatment Means
GB0809627D0 (en) Targeted gene therapy
GB0813213D0 (en) Anti cancer agent
GB0808587D0 (en) Anti cancer agents
GB0700493D0 (en) Cancer treatment